Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report by Tambur, Anat R. et al.
1604  |   amjtransplant.com Am J Transplant. 2018;18:1604–1614.© 2018 The American Society of Transplantation 
and the American Society of Transplant Surgeons
 
Received: 5 January 2018  |  Revised: 25 February 2018  |  Accepted: 20 March 2018
DOI: 10.1111/ajt.14752
M E E T I N G  R E P O R T
Sensitization in Transplantation: Assessment of Risk (STAR) 
2017 Working Group Meeting Report
Anat R. Tambur1,* | Patricia Campbell2 | Frans H. Claas3 | Sandy Feng4 |  
Howard M. Gebel5 | Annette M. Jackson6 | Roslyn B. Mannon7 | Elaine F. Reed8 |  
Kathryn Tinckam9  | Medhat Askar10 | Anil Chandraker11 | Patricia P. Chang12 |  
Monica Colvin13 | Anthony-Jake Demetris14 | Joshua M. Diamond15 | Anne I. Dipchand9 |  
Robert L. Fairchild16 | Mandy L. Ford5 | John Friedewald1  | Ronald G. Gill17 |  
Denis Glotz18 | Hilary Goldberg11 | Ramsey Hachem19 | Stuart Knechtle20 |  
Jon Kobashigawa21 | Deborah J. Levine22 | Joshua Levitsky1 | Michael Mengel2 |  
Edgar Milford11 | Kenneth A. Newell5 | Jacqueline G. O’Leary23 | Scott Palmer20 |  
Parmjeet Randhawa14 | John Smith24 | Laurie Snyder20 | Randall C. Starling16 |  
Stuart Sweet19  | Timucin Taner25 | Craig J. Taylor26 | Steve Woodle27 |  
Adriana Zeevi14 | Peter Nickerson28
1Northwestern University, Chicago, Illinois
2University of Alberta, Edmonton, AB, Canada
3Leiden University Medical Center, Leiden, Netherlands
4UCSF Medical Center, San Francisco, California
5Emory University School of Medicine, Atlanta, Georgia
6Johns Hopkins University, Baltimore, Maryland
7UAB School of Medicine, Birmingham, Alabama
8UCLA Pathology & Laboratory Medicine, Los Angeles, California
9University of Toronto, Toronto, ON, Canada
10Baylor University Medical Center, Dallas, Texas
11Brigham and Women’s’ Hospital, Boston, Massachusetts
12University of North Carolina, Chapel Hill, North Carolina
13University of Michigan, Ann Arbor, Michigan
14University of Pittsburg Medical Center, Pittsburgh, Pennsylvania
15University of Pennsylvania, Philadelphia, Pennsylvania
16Cleveland Clinic, Cleveland, Ohio
17University of Colorado, Denver, Colorado
18Hopital Saint Louis, Paris, France
19Washington University School of Medicine, St. Louis, Missouri
20Duke University School of Medicine, Durham, North Carolina
21Ceder-Sinai Medical Center, Los Angeles, California
22University of Texas, San Antonio, Texas
23Dallas VA Medical Center, Dallas, Texas
Abbreviations: ABMR, antibody-mediated rejection; CDR, complementarity determining region; CNI, calcineurin inhibitor; cPRA, calculated PRA; DSA, donor-specific antibody; MFI, 
mean fluorescent intensity; STAR, Sensitization in Transplantation: Assessment of Risk; TCMR, T cell–mediated rejection.
     |  1605TAMBUR eT Al.
24Royal Brompton & Harefield NHS Foundation Trust, Harefield, UK
25Mayo Clinic, Rochester, Minnesota
26Cambridge University Hospitals, Cambridge, UK
27University of Cincinnati, Cincinnati, Ohio




The presence of preexisting (memory) or de novo donor- specific HLA antibodies 
(DSAs) is a known barrier to successful long- term organ transplantation. Yet, despite 
the fact that laboratory tools and our understanding of histocompatibility have ad-
vanced significantly in recent years, the criteria to define presence of a DSA and as-
sign a level of risk for a given DSA vary markedly between centers. A collaborative 
effort between the American Society for Histocompatibility and Immunogenetics 
and the American Society of Transplantation provided the logistical support for gen-
erating a dedicated multidisciplinary working group, which included experts in histo-
compatibility as well as kidney, liver, heart, and lung transplantation. The goals were 
to perform a critical review of biologically driven, state- of- the- art, clinical diagnostics 
literature and to provide clinical practice recommendations based on expert assess-
ment of quality and strength of evidence. The results of the Sensitization in 
Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing 
recommendations on the definition and utilization of HLA diagnostic testing, and a 
framework for clinical assessment of risk for a memory or a primary alloimmune re-
sponse. The definitions, recommendations, risk framework, and highlighted gaps in 
knowledge are intended to spur research that will inform the next STAR Working 
Group meeting in 2019.
K E Y W O R D S
alloantibody, clinical research/practice, clinical trial design, guidelines, histocompatibility, 
immunobiology, monitoring: immune, sensitization
1  | INTRODUC TION
The presence of preexisting (memory) or de novo donor- specific 
HLA antibodies (DSAs) is a known barrier to successful long- term 
organ transplant.1 Yet, the criteria to define and assign a level of risk 
for a given DSA vary markedly between centers, despite the fact 
that available laboratory tools and our understanding of histocom-
patibility have advanced significantly in recent years. Unfortunately, 
much of our current clinical practice is based on transplant survival 
studies that were designed in the time of older technologies, con-
founding our ability to interpret and implement those results into 
current clinical practice or design new clinical studies. Consequently, 
there is a need to update guidelines for antibody testing and patient 
risk assessment to enable clinical programs to design personalized 
immunosuppression protocols.
A collaborative effort between the American Society for 
Histocompatibility and Immunogenetics and the American Society 
of Transplantation provided the logistical support for generating a 
dedicated multidisciplinary working group that included experts 
in histocompatibility as well as kidney, liver, heart, and lung trans-
plantation. The goals were to perform a critical review of biologi-
cally driven, state- of- the- art, clinical diagnostics literature where 
comprehensive account of methodology was provided and to 
provide clinical practice recommendations based on expert as-
sessment of the strength of evidence (Figure 1). A complete list of 
publications that were reviewed by the working group is provided 
in Table S1.
Participants were divided into smaller discussion groups based 
on their clinical expertise and were tasked with critical (albeit not 
systematic) review of the literature. The literature search focused on 
clinical diagnostics of circulating HLA antibodies. For the purposes 
of the first Sensitization in Transplantation: Assessment of Risk 
(STAR) Working Group report, non- HLA antibodies were considered 
out of scope. Moreover, histologic diagnostics were not considered 
as this falls within the purview of the Banff Foundation for Allograft 
Pathology. To supplement the literature review, a survey was con-
ducted of both clinical and laboratory programs supporting organ 
transplant.
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Subgroups were charged with providing educational primers on 
(1) the definition and use of HLA diagnostic testing and (2) the bio-
logical basis of immunologic naïveté versus memory. Organ- specific 
groups were tasked to establish criteria to assess patients’ risk in 
the context of a naïve- versus- memory immunologic response and to 
use this distinction to inform HLA diagnostic use pretransplant and 
posttransplant. Initial recommendations were formulated, followed 
by face- to- face deliberations of the full group on February 26, 2017, 
at the Arizona Biltmore Hotel in Phoenix, Arizona. Importantly, sub-
groups were asked to identify key knowledge gaps that, if addressed, 
could significantly advance clinical practice. Representatives from 
the US Food and Drug Administration (FDA), National Institutes of 
Health (NIH), and the United Network for Organ Sharing (UNOS) at-
tended as observing stakeholders. It should be noted that the STAR 
Working Group refrained from specific recommendations for ther-
apeutic protocols for 2 major reasons: (1) high- quality evidence is 
lacking to support one approach over another, and (2) for a given pa-
tient, the risk of memory or de novo alloimmunity, and the require-
ments for risk mitigation therapies, varies significantly based on the 
target organ (most notably in the case of liver transplants).
2  | DEFINING THE PRESENCE/ABSENCE 
OF AN HL A ANTIBODY
Solid- phase single- antigen bead (SAB) technology revolutionized 
HLA diagnostics in the past 15 years by detecting very low- level an-
tibodies in patients’ sera with the use of a mean fluorescent intensity 
(MFI) readout.2 There has been much discussion as to the ability to 
set an MFI cut- off for determining the presence or absence of an 
HLA antibody. An objective difficulty lies in the relatively high coef-
ficient of variation (CV) for the assay – a point documented clearly in 
the Clinical Trials in Organ Transplantation/American Recovery and 
Reinvestment–funded HLA antibody standardization study.3 While 
emphasizing that SAB MFI cannot be used as a quantitative assay, the 
study did determine that “MFI positive cutoffs ranging from values 
1000- 1500 yielded a high level of agreement (>90%) in antigen speci-
ficity assignment. The MFI cut- off of 1400 units was found to opti-
mize the correct classification rates for both class I and II kits” (see 
the caveats presented later). The ability to set such a cut- off value, to 
define the presence or absence of an HLA antibody, is critical to im-
proving the quality of clinical trials in the field and allowing for com-
parability between studies, a point specifically emphasized by the 
federal agency observers during the STAR Working Group meeting.
3  | TERMINOLOGY
The survey results, combined with reviews of the relevant literature, 
made it evident that there is confusion with terminology in the com-
munity. It was agreed there must be clarity and consistent use of 
terms to allow comparison between research studies, as well as clini-
cal outcomes, and to facilitate improvement in practice guidelines 
and health system policy.
Specifically, the following major terminology and misuse of terms 
were identified:
1. Mean fluorescence intensity (MFI) ≠ titer. A high MFI value is often 
referred to as a high titer antibody but only rarely indicates the ac-
tual testing of serum by dilution studies. Some antibodies with rel-
atively high MFI values may dilute rather quickly and therefore do 
not qualify as high titer antibodies.4 Moreover, HLA antibody SAB 
MFI assessment is not licensed by the FDA as a quantitative assay. 
Determination of antibody titer is important as it is likely to have 
implications on the injurious qualities of that antibody and a refer-
ence point for determining efficacy of desensitization therapy.5
2. 0% Calculated PRA (cPRA) ≠ immunologically naïve. The fact that a pa-
tient has no detectable HLA antibodies does not infer that he or she 
F IGURE  1 Expert assessment of strength of evidence
Patients Clinicians Policy
1 Recommend Most would want Most would do Supports policy
2 Suggest Majority would want but many would not
Different choices for 
different paents
Substanve debate to 
follow







EO There is no specific evidence to address recommendaon, however it aligns with standard of care 
and would be agreed by a majority of experts that no specific evidence on the topic needs to be 
generated, nor would it be expected to be generated 
There is absence of evidence and/or the working group expert opinion only was used, or
RCT or Very strong evidence of associaon with no confounders
Strong evidence of associaon or evidence of a dose response gradient
Observaonal study
Other types of studies or serious limitaons to study quality 
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is immunologically naïve with regard to HLA antigens. It is entirely 
possible that a nontransplanted patient has been exposed and re-
sponded to an allo-HLA antigen through pregnancy or transfusion 
yet does not have a detectable HLA antibody in the current sera.
3. Acceptable HLA mismatch ≠ immunologically naïve. The term “unac-
ceptable HLA antigens” is used in the context of listing a patient’s 
HLA antibody specificities in UNet to avoid donor offers that the 
clinical program is not willing to cross due to the risk associated with 
a memory response. Not uncommonly, it is assumed that the re-
maining “acceptable antigens” infers that there is no immune mem-
ory or that there is no HLA antibody specific for the “acceptable 
antigen.” This is entirely a false premise – in many instances just 
because a DSA MFI is below the program’s “risk threshold” does not 
mean the antibody does not exist and that the recipient is immuno-
logically naïve to that mismatch and therefore at no or minimal risk.
4. Pretransplant DSA titer ≠ posttransplant memory response. It is often in-
ferred that the amount of antibody pretransplant can be used to pre-
dict the risk and intensity of the posttransplant recall response. This is 
completely without basis – at present, we have no tools to determine 
if a low titer antibody will remain low or rapidly increase in titer.
5. Complement (C’) binding activity in vitro ≠ in vivo c’ binding activ-
ity. While certain antibody subclasses do have higher affinity for 
C1q binding, complement activation is largely a consequence of 
a high concentration of DSAs.4,6,7 Indeed, it has been shown that 
activation of C1q requires the presence of 6 antibody molecules in 
close proximity.8 Consequently, C1q-positive DSAs in the serum, 
similar to IgG DSAs in the serum, should be considered in the con-
text of gradations of the antibody’s levels rather than as yes/no 
responses. Moreover, patients with a C1q-negative DSA in the 
serum can frequently have C4d-positive antibody-mediated rejec-
tion (ABMR) in the tissue indicating that a negative C1q assay does 
not infer the DSAs are incapable of activating complement in vivo.9 
Therefore, while emerging data suggest C1q-positive DSAs may 
indicate a potential risk for adverse graft outcomes, more research 
in this regard is required to clearly demonstrate its distinct utility.10
6. Eplet ≠ epitope. A commonly misused term is “epitope” instead of 
“eplet.” “Epitope” refers to the complete contact area between an 
antibody and an antigen. “Eplet” is a portion of the epitope that in 
theory forms the third CDR of the immunoglobulin variable heavy 
chain (CDR H3) antibody binding site, defined purely based on amino 
acid mismatching between donor and recipient (i.e., represents the 
potential functional epitope of the antibody determining specificity, 
whereas the entire structural epitope, composed of the binding by 
all 6 CDRs, determines antibody avidity).11,12 Currently, only a sub-
set of the theoretical eplets have been proved to be antigenic.
4  | QUALIT Y AND COMPREHENSIVE USE 
OF HL A DIAGNOSTIC S
It was identified that the quality and comprehensive use of HLA 
diagnostics vary greatly in the published literature. This is in part 
related to the retrospective nature of many reports that examine 
longitudinal outcomes in cohorts before 2010, after which UNOS 
started to mandate more comprehensive HLA loci typing as well as 
solid phase testing for HLA antibodies. Key gaps remain that need to 
be considered in interpreting the literature:
1. Lack of donor HLA loci typing does not equal absence of a DSA di-
rected to that HLA loci. Presence of HLA-DSAs is (at times) deter-
mined in the absence of comprehensive donor HLA typing. The 
corollary is that absence of DSAs for a given loci cannot be rigor-
ously determined if the donor typing at that loci is not available.
2. Lack of high-resolution typing cannot be substituted by statistical as-
sumptions of the missing data. Given the complexity of HLA genet-
ics, and its polymorphism in different ethnic groups, imputation of 
missing HLA data may introduce substantial bias and may lead to 
false conclusions, especially with regards to HLA class II antigens. 
Currently available frequency tables may support clinical consul-
tation for individual patient management, but in the vast majority 
of the cases, this is not sufficient for clinical trials adjusting for the 
confounding effect of HLA mismatching on outcomes.
3. Failure to routinely use methods to rule out serum inhibitors in HLA 
antibody assays leads to underrecognition of DSA. Inhibitors, such as 
endogenous C’ activation in vitro, can block the ability of second-
ary antibodies to appropriately recognize DSA binding to the SAB, 
producing low MFI readings and an inaccurate interpretation that 
a DSA is absent or at a low level.4, 13
4. Failure to consider shared epitopes between solid phase beads leads 
to underrecognition of DSA. While the aforementioned MFI cut-off 
between 1000 and 1500 units is generally optimal for recognition 
of a DSA specificity, it is nonetheless a guideline and not an abso-
lute. When a number of beads share the same DSA epitope, it is 
entirely possible to have a DSA with the MFI <1000 on all beads. 
Knowledge of shared epitopes is therefore essential for proper 
interpretation of SAB assays.
To improve “precision” and “personalized” medicine, the consensus 
was that comprehensive HLA diagnostics must become the standard 
of care and most certainly have to be imbedded in clinical trial research 
going forward. The STAR Working Group recommendations for HLA 
antigen typing and antibody testing are summarized in Figure 2.
5  | IMMUNE MEMORY
Immunologic memory is the ability of the immune system to respond 
rapidly and with vigor on reencounter with the same antigen. Modern 
immunology now demonstrates that infection or vaccination results in 
the generation of long- lived subsets of phenotypically, functionally, and 
metabolically distinct B and T cells. Memory T and B cells are the progeny 
of antigen- specific naïve cells that have been clonally expanded in the 
course of an immune response and that survive even after antigen has 
been eliminated. They reside in specific anatomic locations, have distinct 
phenotypes, and are uniquely poised to confer immediate protection and 
1608  |     TAMBUR eT Al.
generate secondary responses that are more rapid and of higher magni-
tude than primary responses against the same antigen.14 In transplant 
recipients, donor- reactive memory T and B cells can arise from prior 
exposure to foreign HLA via prior blood transfusion, transplantation, or 
pregnancy. Additionally, heterologous immune mechanisms, whereby T 
cell responses elicited by infectious pathogens are cross- reactive with 
donor antigens, provide another potential source of alloreactive mem-
ory T cells in transplant recipients.15,16 Given that immune memory is a 
known barrier to graft survival,17 although its impact can vary by organ 
type, the STAR Working Group recommendations are aimed at detecting 
and evaluating the immune status of the patient. That said, it is important 
to recognize, at least as currently measured, that the in vitro assessment 
of immune memory has severe limitations and gaps that fail to incorpo-
rate aspects of well- described immunobiology.
6  | CLINIC AL ME A SUREMENT OF IMMUNE 
MEMORY
Currently, classification of patients as “sensitized” or “naïve” is 
strongly influenced by the most recent circulating HLA antibody 
test – percent PRA and specific HLA antibody identification. While 
this information is beneficial to predict lymphocyte crossmatch 
results, it does not provide complete and accurate information re-
garding the patient’s sensitization history and his or her likelihood 
to have a recall memory response against the transplanted organ. 
Specifically, patients with 0% PRA in a current serum sample may 
have had historic HLA antibodies after a sensitizing event that 
may or may not be apparent to the clinician based on availability 
of sera and frequency and length of historic HLA antibody testing. 
Moreover, recent literature demonstrates that HLA specific B cell 
memory may be present even in the absence of detectable HLA an-
tibodies.18,19 The meeting highlighted that our current “memory as-
says” are limited to detecting circulating HLA antibodies at a specific 
time- point (ie, flow PRA and the SAB assays) and thus focus on only 
a small portion of the memory alloimmune response. Clearly, we are 
only beginning to scratch the surface of detecting donor- specific B 
and T cell memory (eg, interferon- γ enzyme- linked immunosorbent 
spot [ELISpot] assay) pretransplant.20 The STAR Working Group de-
veloped definitions for alloimmune memory (Figure 3) and recom-
mendations to evaluate a patient’s potential for alloimmune memory 
(Figure 4).
F IGURE  2 Recommendations for HLA 
typing and antibody diagnostic testing
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7  | PRIMARY (NAÏVE OR DE NOVO) 
ALLOIMMUNE RESPONSE
It is difficult to document that a patient is truly “naïve” for a given 
mismatched alloantigen; rather, it is generally expressed in terms of 
relative risk for a memory response to that alloantigen on the basis of 
patient history and HLA antibody testing (see earlier). Confounding 
the definition of “naïve,” the STAR Working Group found the trans-
plant literature inconsistent in comprehensively assessing the 
presence of pretransplant alloimmune memory, a requirement if 
concluding that a posttransplant alloimmune response is de novo. 
Key questions thus arise: Can one be assured an observed alloim-
mune response is de novo versus memory? Does posttransplant 
distinction between memory versus primary alloimmunity have 
clinical implications? Can one assess an individual’s risk for a primary 
immune response to a given mismatched alloantigen?
The confidence in assigning an alloimmune response as de 
novo versus memory is not difficult when comprehensive state- 
of- the- art assessment fails to detect DSA pretransplant and T 
cell–mediated rejection (TCMR) or ABMR occurs for the first time 
late (ie, >6 months) posttransplant. The challenge resides when 
these requirements are not met. Moreover, at least 4 other pa-
rameters further confound classification: (1) immunogenicity of a 
given mismatched alloantigen, (2) immunogenicity of a given trans-
planted organ (eg, kidney ≫ liver), (3) immune responsiveness of 
the individual (eg, younger ≫ older), and (4) the adequacy of im-
munosuppression given parameters 1 to 3. Emerging literature is 
bringing all of these into focus. For example, recent studies ex-
cluding pretransplant DSAs using state- of- the- art HLA diagnostics 
where target tacrolimus trough levels were between 8 and 12 ng/
mL in the first 3 months and 7 to 12 ng/mL for the first year did 
not report a new DSA on serial posttransplant screening before 
6 months. In comparison, if the target tacrolimus trough level was 
between 6 and 9 ng/mL during the first 3 months, a new DSA inci-
dence of 7.4% at 1 month was observed.21-23 Given this complex-
ity, the STAR Working Group concluded that in general, a new DSA 
observed in the first 2 weeks posttransplant likely represents a 
memory response. Between 2 weeks and 3 months, as immuno-
suppression is weaned and cells are repopulated from depletion 
therapy (when used); then both memory and de novo alloimmunity 
may emerge. After 3 months, the later the onset of a new DSA, 
the more likely that it is related to de novo alloimmunity. Clearly, 
F IGURE  3 Working definitions for 
alloimmune memory responses
• Latent Potential for an Alloimmune Memory Response: One or more of,
• A history of a sensitizing event;
• Non-DSA HLA antibody detected at one or more time points prior to transplant;
• Non-DSA HLA antibody detected at the time of transplant.
• Active Potential for an Alloimmune Memory Response: Donor specific antibody (DSA) are 
present at the time of transplant or in a historical serum sample tested, representing a risk for 
DSA associated injury.
• Alloimmune Memory Response: The development post-transplant at any time of an antibody 
that was detected prior to transplant and/or the development of a new DSA in the first 2 weeks 
post-transplant. Caveat to consider:
• Development of a new DSA between 2 weeks and 3 months may still represent 
memory.
F IGURE  4 Recommendations for 
evaluating a patient’s potential for 
alloimmune memory
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these are broad guidelines and represent an area for further study 
and refinement to determine the relative contribution of memory 
and primary alloimmunity early (ie, <6 months) posttransplant. 
However, the distinction may prove very relevant as literature is 
reporting differences in outcomes related to memory versus de 
novo DSA- associated ABMR.24,25 Similarly, whether treatment 
protocols are equally effective for both memory and primary allo-
immunity requires further research.
Literature rigorously defining an alloimmune response as de 
novo has reported that the level of HLA whole antigen mismatch 
does not accurately reflect the immunogenic risk of a given donor 
to elicit a de novo alloresponse.26 Indeed, for a given level of HLA 
serologic antigen mismatch, at the molecular level, the donor and 
recipient of a donor–recipient pair may be very similar to one an-
other or quite disparate. New computational tools are emerging 
that allow accurate quantitation at the HLA molecular mismatch 
level (eg, in terms of amino acid polymorphisms or differences in 
electrostatic charge) for any donor–recipient combination, which 
may allow more accurate assessment of a patient’s risk for a de 
novo alloimmune response postransplant.27,28 While the optimal 
computational methods and threshold values to assign risk are yet 
to be determined and validated, especially in diverse genetic back-
grounds and across all organ transplants, the STAR Working Group 
saw this area as one holding great promise for the field requiring 
immediate investment. It may allow for personalized immunosup-
pression and, in particular, minimization to avoid unwanted side 
effects.
8  | ALLOIMMUNE RISK A SSESSMENT
Based on the aforementioned discussion of the biology of memory 
and primary alloimmune responses, the STAR Working Group con-
structed a general framework for assigning risk independently for 
memory and primary alloimmune responses at the time of trans-
plant. Summarized in Table 1, the framework proposes that risk can 
be broadly assigned by using currently available state- of- the- art HLA 
diagnostics. The novel aspect of this framework is the assignment 
of 2 types of risk (eg, 1 for memory and 1 for de novo alloimmunity). 
While the de novo risk assignment on the basis of molecular HLA 
mismatch is yet to be optimized, the STAR Working Group saw the 
creation of the framework as critical to foster research in the field 
of HLA immunogenicity and to ultimately define immunodominant 
HLA epitopes driving TCMR and ABMR. The use of the framework 
is seen as allowing individual transplant programs to first and fore-
most define the memory and primary alloimmune risks present for a 
given patient and organ transplant type and then to either avoid the 
risk or develop tailored induction and maintenance immunosuppres-
sive therapies to address the risk. As stated at the outset, protocols 
vary widely across clinical programs, and the literature does not cur-
rently have high- quality evidence to recommend one protocol over 
another. It is hoped that this framework will drive clinical research to 
address this gap.
9  | ORGAN- SPECIFIC HL A DIAGNOSTIC 
A SSESSMENT GUIDELINES
There was broad consensus among the organ- specific groups for the 
recommendations contained in Figures 1 to 3. However, immedi-
ate pretransplant evaluation and posttransplant assessment varied 
among the organ- specific groups, and these are reflected in Table 2, 
mainly concerning the grade and strength of the recommendations. 
Of note, while there was general agreement in regard to the need for 
posttransplant DSA monitoring, especially in the context of memory, 
the lack of high- quality evidence precludes the STAR Working Group 
from making any specific recommendations as to the frequency and 
duration—at this point, it should be a program- specific decision.
10  | KE Y KNOWLEDGE GAPS
The STAR Working Group identified general as well as organ- specific 
gaps in the current knowledge that should be addressed within the 
following broad categories:
1. Risk Stratification for Memory and Primary Alloimmune 
Responses
The literature review, as well as the survey, elucidated the lack of 
integration between HLA antibody information and current knowl-
edge of immunobiological processes as a tool to guide clinical practice. 
In general, HLA antibodies are evaluated as present/absent rather than 
evaluating the patient’s immune- sensitization status; the type of im-
munization (ie, pregnancy vs transfusion vs prior transplant); strength 
of antibodies; and trajectory of antibody responses. While this is a gap 
in education, a more fundamental deficit relates to the absence of tests 
to detect the potential presence of immune memory in the absence 
of circulating HLA antibodies. Development of robust high- throughput 
tools to identify and quantify T cell and B cell memory is required for 
pretransplant risk assessment and tailoring of immunosuppression 
protocols pretransplant and posttransplant.
Improved matching algorithms, beyond pretransplant crossmatch 
and the current HLA-A, -B, -DR matching scheme, are required. This 
will help minimize the risk of de novo HLA antibodies posttransplant 
and lead to improved graft survival. Similarly, research to define the 
effects of different immunosuppression regimens on the likelihood 
of developing de novo HLA DSA and/or TCMR should lead to more 
individualized treatment protocols.
2. Desensitization/crossing HLA antibody barriers
Multiple desensitization protocols are currently available.29-32 
However, it is not clear how to determine the optimal patient popu-
lation who may respond to each of these approaches, or to predict 
whether the response will be sufficient to bridge those patients to 
transplantation, or if a specific protocol is even required in the case of 
liver transplants. Assays to monitor the efficacy of these treatments 
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are lacking, and thus the ability to compare between the different 
protocols is limited. Moreover, the effectiveness of desensitization in 
targeting memory (especially B cells) is completely unknown. It is cur-
rently not clear whether some DSA attributes are more detrimental 
than others and what the relationships are between these character-
istics (eg, complement binding antibodies, titers, antibody subclasses, 
the dynamics of isotype switching over time, the impact of FcγR gen-
otypes, etc.).33
3. Posttransplant monitoring
Determining the usefulness of regular screening for DSA, the fre-
quency, and the associated cost- benefit is required for both memory 
and de novo alloimmune monitoring in all organs. While the epidemi-
ology of memory and de novo alloimmunity and their natural history 
are becoming clearer, especially for kidneys, there is a need for their 
further evaluation in all organs, especially in the context of nonwhite 
genetics, to determine risk factors and rates of progression—critical for 
the future design of prevention and intervention trials. The use of HLA 
diagnostics in monitoring response to treatment is also in its infancy. 
As more therapeutic agents become available, defining a noninvasive 
tool (eg, DSA attributes, other novel assays) that correlates with effec-
tive therapy will be required).
11  | C ALL FOR IMMEDIATE AC TION
Two key themes that emerged from the Working Group are the 
following. First, currently, there are no minimal guidelines for the 
details of information required for publications related to HLA anti-
bodies in the context of solid organ transplantation. The lack of suf-
ficient details prohibits in- depth understanding of the differences 
and similarities between studies and results in confusion. This can be 
resolved by requiring minimal criteria for publication. Second, there 
is a pressing need to create centralized registries for highly sensi-
tized patients and HLA- incompatible transplants. This is especially 
true for those transplanted with living donors in kidney paired ex-
change programs as well as with deceased donors when prioritized 
by the kidney allocation system; Registries should also be created 
for patients who experience ABMR posttransplant. The registries 
should collect HLA antibody and typing information in a streamlined 
fashion and house data defining treatment protocols and transplant 
TABLE  2 Organ- specific recommendations
*                        (34) 
**                     (21,35,36) 
***                    (22) 
DSA, donor-specific antibody; CNI, calcineurin inhibitor; ABMR, antibody-mediated rejection.
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outcome in a constant and consistent manner. These data registries 
could also be mined for epidemiologic information (eg, race- specific 
outcome).
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